CXCL8 and rheumatoid arthritis: RA neutrophil chemotaxis toward the synovial fluid rich CXCL8 (IL-8) was blocked with the Janus kinase inhibitors (JAKi) (Mitchell et al., 2017), along with reduced neutrophil and T-cell numbers observed in the joints of RA patients treated with barictinib (Tanaka et al., 2018) – suggesting JAKi have potential therapeutic benefit by limiting leukocyte migration in arthritic patients.